BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

292 related articles for article (PubMed ID: 31214182)

  • 1. Improving Clinical Manufacturing of IL-15 Activated Cytokine-Induced Killer (CIK) Cells.
    Bremm M; Pfeffermann LM; Cappel C; Katzki V; Erben S; Betz S; Quaiser A; Merker M; Bonig H; Schmidt M; Klingebiel T; Bader P; Huenecke S; Rettinger E
    Front Immunol; 2019; 10():1218. PubMed ID: 31214182
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Adoptive immunotherapy with cytokine-induced killer cells for patients with relapsed hematologic malignancies after allogeneic hematopoietic cell transplantation.
    Laport GG; Sheehan K; Baker J; Armstrong R; Wong RM; Lowsky R; Johnston LJ; Shizuru JA; Miklos D; Arai S; Benjamin JE; Weng WK; Negrin RS
    Biol Blood Marrow Transplant; 2011 Nov; 17(11):1679-87. PubMed ID: 21664472
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Haploidentical Natural Killer Cells Infused before Allogeneic Stem Cell Transplantation for Myeloid Malignancies: A Phase I Trial.
    Lee DA; Denman CJ; Rondon G; Woodworth G; Chen J; Fisher T; Kaur I; Fernandez-Vina M; Cao K; Ciurea S; Shpall EJ; Champlin RE
    Biol Blood Marrow Transplant; 2016 Jul; 22(7):1290-1298. PubMed ID: 27090958
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The cytotoxic potential of interleukin-15-stimulated cytokine-induced killer cells against leukemia cells.
    Rettinger E; Kuçi S; Naumann I; Becker P; Kreyenberg H; Anzaghe M; Willasch A; Koehl U; Bug G; Ruthardt M; Klingebiel T; Fulda S; Bader P
    Cytotherapy; 2012 Jan; 14(1):91-103. PubMed ID: 21973023
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immunomagnetic selection or irradiation eliminates alloreactive cells but also reduces anti-tumor potential of cytokine-induced killer cells: implications for unmanipulated cytokine-induced killer cell infusion.
    Rettinger E; Kreyenberg H; Merker M; Kuçi S; Willasch A; Bug G; Ullrich E; Wels WS; Bonig H; Klingebiel T; Bader P
    Cytotherapy; 2014 Jun; 16(6):835-44. PubMed ID: 24582456
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Epstein-Barr virus-specific cytokine-induced killer cells for treatment of Epstein-Barr virus-related malignant lymphoma.
    Pfeffermann LM; Pfirrmann V; Huenecke S; Bremm M; Bonig H; Kvasnicka HM; Klingebiel T; Bader P; Rettinger E
    Cytotherapy; 2018 Jun; 20(6):839-850. PubMed ID: 29754771
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In-vitro influence of mycophenolate mofetil (MMF) and Ciclosporin A (CsA) on cytokine induced killer (CIK) cell immunotherapy.
    Bremm M; Huenecke S; Zimmermann O; Pfirrmann V; Quaiser A; Bonig H; Soerensen J; Klingebiel T; Rettinger E; Bader P; Cappel C
    J Transl Med; 2016 Sep; 14(1):264. PubMed ID: 27620209
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Preparation of Cytokine-activated NK Cells for Use in Adoptive Cell Therapy in Cancer Patients: Protocol Optimization and Therapeutic Potential.
    van Ostaijen-ten Dam MM; Prins HJ; Boerman GH; Vervat C; Pende D; Putter H; Lankester A; van Tol MJ; Zwaginga JJ; Schilham MW
    J Immunother; 2016; 39(2):90-100. PubMed ID: 26849078
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Human interferon-alpha increases the cytotoxic effect of CD56(+) cord blood-derived cytokine-induced killer cells on human B-acute lymphoblastic leukemia cell lines.
    Durrieu L; Gregoire-Gauthier J; Dieng MM; Fontaine F; le Deist F; Haddad E
    Cytotherapy; 2012 Nov; 14(10):1245-57. PubMed ID: 22974386
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cytomegalovirus-specific cytokine-induced killer cells: concurrent targeting of leukemia and cytomegalovirus.
    Pfirrmann V; Oelsner S; Rettinger E; Huenecke S; Bonig H; Merker M; Wels WS; Cinatl J; Schubert R; Klingebiel T; Bader P
    Cytotherapy; 2015 Aug; 17(8):1139-51. PubMed ID: 26072027
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CIK cells from recurrent or refractory AML patients can be efficiently expanded in vitro and used for reduction of leukemic blasts in vivo.
    Wang Y; Bo J; Dai HR; Lu XC; Lv HY; Yang B; Wang T; Han WD
    Exp Hematol; 2013 Mar; 41(3):241-52.e3. PubMed ID: 23123634
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical grade manufacturing of genetically modified, CAR-expressing NK-92 cells for the treatment of ErbB2-positive malignancies.
    Nowakowska P; Romanski A; Miller N; Odendahl M; Bonig H; Zhang C; Seifried E; Wels WS; Tonn T
    Cancer Immunol Immunother; 2018 Jan; 67(1):25-38. PubMed ID: 28879551
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Quantity and Quality Reconstitution of NKG2A
    Hu LJ; Zhao XY; Yu XX; Lv M; Han TT; Han W; Huang XJ
    Biol Blood Marrow Transplant; 2019 Jan; 25(1):1-11. PubMed ID: 30142416
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Interleukin-15 enhances cytokine induced killer (CIK) cytotoxic potential against epithelial cancer cell lines via an innate pathway.
    Iudicone P; Fioravanti D; Cicchetti E; Zizzari IG; Pandolfi A; Scocchera R; Fazzina R; Pierelli L
    Hum Immunol; 2016 Dec; 77(12):1239-1247. PubMed ID: 27615504
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Thymoglobulin efficiently expands cytokine-induced killer cells in a clinical-grade culture protocol].
    Chen W; Lin D; Jiang Z; Yang Z; Song S; Zhou J; Zhou L; Sun Y; Yu H; Ma D
    Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2014 Jul; 30(7):681-5, 690. PubMed ID: 25001928
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cytotoxic potential of IL-15-activated cytokine-induced killer cells against human neuroblastoma cells.
    Cappel C; Huenecke S; Suemmerer A; Erben S; Rettinger E; Pfirrmann V; Heinze A; Zimmermann O; Klingebiel T; Ullrich E; Bader P; Bremm M
    Pediatr Blood Cancer; 2016 Dec; 63(12):2230-2239. PubMed ID: 27433920
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The Synergistic Use of IL-15 and IL-21 for the Generation of NK Cells From CD3/CD19-Depleted Grafts Improves Their
    Heinze A; Grebe B; Bremm M; Huenecke S; Munir TA; Graafen L; Frueh JT; Merker M; Rettinger E; Soerensen J; Klingebiel T; Bader P; Ullrich E; Cappel C
    Front Immunol; 2019; 10():2816. PubMed ID: 31849984
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Chimeric antigen receptor-engineered cytokine-induced killer cells overcome treatment resistance of pre-B-cell acute lymphoblastic leukemia and enhance survival.
    Oelsner S; Wagner J; Friede ME; Pfirrmann V; Genßler S; Rettinger E; Buchholz CJ; Pfeifer H; Schubert R; Ottmann OG; Ullrich E; Bader P; Wels WS
    Int J Cancer; 2016 Oct; 139(8):1799-809. PubMed ID: 27253354
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Increase in Efficacy of Checkpoint Inhibition by Cytokine-Induced-Killer Cells as a Combination Immunotherapy for Renal Cancer.
    Dehno MN; Li Y; Weiher H; Schmidt-Wolf IGH
    Int J Mol Sci; 2020 Apr; 21(9):. PubMed ID: 32349280
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cord blood-derived cytokine-induced killer cells combined with blinatumomab as a therapeutic strategy for CD19
    Golay J; Martinelli S; Alzani R; Cribioli S; Albanese C; Gotti E; Pasini B; Mazzanti B; Saccardi R; Rambaldi A; Introna M
    Cytotherapy; 2018 Aug; 20(8):1077-1088. PubMed ID: 30093325
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.